StreetInsider.com News Articles

Form 4 Pharvaris N.V. For: Sep 09 Filed by: Glassman Robert

Fri, 11 Sep 2026 12:25:00 -0400

si-local-file:///var/storage/secattach/20260911/27051999.html

Form 144 Pharvaris N.V. Filed by: Lesage Anne

Thu, 10 Sep 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260910/27049164.html

Pharvaris B.V. (PHVS) PT Raised to $44 at Guggenheim

Thu, 10 Sep 2026 07:10:47 -0400

(Updated - September 10, 2026 7:10 AM EDT)

Guggenheim analyst Debjit Chattopadhyay raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $44.00 (from $40.00) while maintaining a Buy rating.

The analyst commented: "CHAPTER-3 delivered injectable-like efficacy—83% & 87% attack reduction overall & in Type 1/2 HAE patients, respectively—with the convenience of QD oral medicine. Pharvaris becomes the one-stop-shop for all things HAE, potentially increasing its strategic optionality. However, two >5x ULN transaminase elevations without bilirubin increases kept a lid on the stock despite stellar efficacy. Company described the LFTs as asymptomatic—one patient discontinued treatment and the other completed the study—with possible

Pharvaris B.V. (PHVS) PT Raised to $44 at Guggenheim

Thu, 10 Sep 2026 07:10:47 -0400

(Updated - September 10, 2026 7:10 AM EDT)

Guggenheim analyst Debjit Chattopadhyay raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $44.00 (from $40.00) while maintaining a Buy rating.

Pharvaris B.V. (PHVS) PT Raised to $52 as RBC Capital Sees Upside

Wed, 09 Sep 2026 07:55:48 -0400

(Updated - September 9, 2026 7:55 AM EDT)

RBC Capital analyst Nevin Varghese raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $52.00 (from $51.00) while maintaining a Outperform rating.

The analyst commented: "Best CHAPTER Yet: Pivotal Data Cements Deucrictibant as a Compelling Oral HAE Prophylaxis; CHAPTER-3 data looks to be a homerun with the ph.III recapitulating and even improving upon prior ph.II data, combined with a relatively clean safety profile; we had a chance to catch up with management following the more detailed data presentation and get KOL feedback. Given the compelling efficacy data that rivals injectable-class reductions, we are

Pharvaris B.V. (PHVS) PT Raised to $52 as RBC Capital Sees Upside

Wed, 09 Sep 2026 07:55:48 -0400

(Updated - September 9, 2026 7:55 AM EDT)

RBC Capital analyst Nevin Varghese raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $52.00 (from $51.00) while maintaining a Outperform rating.

Pharvaris B.V. (PHVS) PT Raised to $62 at Morgan Stanley

Wed, 09 Sep 2026 07:54:28 -0400

Morgan Stanley analyst Maxwell Skor raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $62.00 (from $46.00) while maintaining a Overweight rating.

H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)

Wed, 09 Sep 2026 07:27:30 -0400

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $60.00 price target on Pharvaris B.V. (NASDAQ: PHVS).

The analyst commented: "This morning, Pharvaris announced that the Phase 3 trial CHAPTER-3 evaluating once-daily deucrictibant extended-release (XR) oral tablet for the prevention of hereditary angioedema (HAE) attacks met its primary endpoint with an 83% reduction in mean monthly attack rate vs placebo (95% CI: 72–90%; p<0.0001) across all three HAE types, and with an 87% reduction in the 80 participants with Type 1 or Type 2 disease in an additional analysis not adjusted for multiplicity (link to deck). All secondary efficacy

Pharvaris B.V. (PHVS) PT Raised to $62 at RBC Capital

Wed, 09 Sep 2026 07:23:26 -0400

RBC Capital analyst Nevin Varghese raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $62.00 (from $52.00) while maintaining a Outperform rating.

Pharvaris B.V. (PHVS) PT Raised to $65 at Wells Fargo

Wed, 09 Sep 2026 05:50:09 -0400

Wells Fargo analyst Yanan Zhu raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $65.00 (from $55.00) while maintaining a Overweight rating.

The analyst comments "Deucrictibant showed injectable like efficacy, reducing attack rates by 83% vs pbo, across all HAE subtypes and by 87% in Types 1 and 2. Reiterate OW rating & raise our DCF-based PT to $65 (from $55) assuming a 90% PoS in the prophylactic indication. Injectable like efficacy in comparable HAE Types. Deucrictibant XR's 87% percent reduction in pbo adjusted attack rates in HAE Types 1 & 2 exactly matches the performance of TAKHZYRO, ANDEMBRY, and

Pharvaris B.V. (PHVS) PT Raised to $65 at Wells Fargo

Wed, 09 Sep 2026 05:50:09 -0400

Wells Fargo analyst Yanan Zhu raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $65.00 (from $55.00) while maintaining a Overweight rating.

Pharvaris B.V. (PHVS) PT Raised to $79 at Citizens on Agent Trial Success

Wed, 09 Sep 2026 04:12:01 -0400

Citizens analyst Jonathan Wolleben raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $79.00 (from $75.00) while maintaining a Market Outperform rating.

The analyst commented, "PHVS's (Wolleben, MO, $79 PT) results with a daily oral pill and NTLA's one-and-done approaches are on the opposite ends of the spectrum in HAE prophylaxis. Overall, we view the success of these agents in trials as a positive that can expand the market and improve patient care though new modalities."

Pharvaris B.V. (PHVS) PT Raised to $79 at Citizens on Agent Trial Success

Wed, 09 Sep 2026 04:12:01 -0400

Citizens analyst Jonathan Wolleben raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $79.00 (from $75.00) while maintaining a Market Outperform rating.

Pharvaris B.V. (PHVS) PT Raised to $75 at Oppenheimer

Tue, 08 Sep 2026 14:47:59 -0400

Oppenheimer analyst Jeff Jones raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $75.00 (from $50.00) while maintaining a Outperform rating.

The analyst comments "This morning, PHVS reported outstanding efficacy from the pivotal CHAPTER-3 study of deucrictibant XR in HAE prophylaxis (slides, PR). The results landed between our "Bull" and "Best Case" scenarios, as we've outlined previously (Note). The results effectively matched the previously reported Phase 2 results and those of market-leading injectable (SC) Takhzyro, and put PHVS's deucrictibant XR well ahead of BCRX's marketed Orladeyo. This stock has moved higher today, +9% vs. the XBI -1%, with management positioning

Pharvaris B.V. (PHVS) PT Raised to $75 at Oppenheimer

Tue, 08 Sep 2026 14:47:59 -0400

Oppenheimer analyst Jeff Jones raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $75.00 (from $50.00) while maintaining a Outperform rating.

Pharvaris B.V. (PHVS) PT Raised to $75 at Oppenheimer

Tue, 08 Sep 2026 14:47:59 -0400

Oppenheimer analyst Jeff Jones raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $75.00 (from $50.00) while maintaining a Outperform rating.

Pharvaris B.V. (PHVS) PT Raised to $65 at Cantor Fitzgerald

Tue, 08 Sep 2026 10:43:36 -0400

Cantor Fitzgerald analyst Steven Seedhouse raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $65.00 (from $46.00) while maintaining a Overweight rating.

Pharvaris HAE drug hits 83% attack rate cut in phase 3 trial

Tue, 08 Sep 2026 06:50:40 -0400

Pharvaris (Nasdaq: PHVS) announced that its CHAPTER-3 Phase 3 clinical trial of deucrictibant extended-release (XR) tablet met its primary endpoint, reducing hereditary angioedema (HAE) attack rates by 83% versus placebo (p<0.0001) in participants with all three types of HAE.

The double-blind, placebo-controlled study enrolled 85 participants from 21 countries, randomized in a 2:1 ratio to receive deucrictibant XR at 40 mg once daily (N=55) or placebo (N=30) over 24 weeks. In the 80 participants with HAE Type 1 or Type 2, the mean monthly attack rate was 87% lower in the deucrictibant XR group compared to placebo. All secondary efficacy endpoints

Pharvaris HAE drug hits 83% attack rate cut in phase 3 trial

Tue, 08 Sep 2026 06:50:40 -0400

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

Tue, 08 Sep 2026 06:50:00 -0400

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE
87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2
All secondary efficacy endpoints met with statistical significance
Well-tolerated safety profile of deucrictibant XR demonstrated
Conference call and webcast today at 8:00 a.m. EDT

ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

Tue, 08 Sep 2026 06:50:00 -0400

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE
87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2
All secondary efficacy endpoints met with statistical significance
Well-tolerated safety profile of deucrictibant XR demonstrated
Conference call and webcast today at 8:00 a.m. EDT

Pharvaris presents deucrictibant data at Bradykinin Symposium 2026

Thu, 03 Sep 2026 06:51:40 -0400

Pharvaris (Nasdaq: PHVS) presented translational, nonclinical, and clinical data on its investigational drug deucrictibant at the Bradykinin Symposium 2026, held Sept. 3-4 in Berlin, Germany.

The presentations covered several areas, including bradykinin science, on-demand therapy, combination treatment, long-term prophylaxis, and cardiovascular safety.

In the Phase 3 RAPIDe-3 trial, a regional subgroup analysis showed that deucrictibant immediate-release (IR) capsule was associated with shorter median time to onset of symptom relief compared with placebo — 1.20 hours in North America and 1.28 hours in Europe and the rest of the world. Complete attack resolution occurred at a median of 11.61 hours and 12.04 hours

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

Thu, 03 Sep 2026 06:50:00 -0400

ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations from the Bradykinin Symposium 2026, which will take place from September 3-4, 2026, in Berlin, Germany.

“The breadth of data being presented at the Bradykinin Symposium is reflective of Pharvaris’ ongoing commitment to the scientific understanding of the biology and pathophysiology of

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

Thu, 03 Sep 2026 06:50:00 -0400

ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations from the Bradykinin Symposium 2026, which will take place from September 3-4, 2026, in Berlin, Germany.

“The breadth of data being presented at the Bradykinin Symposium is reflective of Pharvaris’ ongoing commitment to the scientific understanding of the biology and pathophysiology of

Form 4 Pharvaris N.V. For: Aug 14 Filed by: Modig Berndt

Tue, 18 Aug 2026 11:49:00 -0400
si-local-file:///var/storage/secattach/20260818/26942836.html